Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Indications And Dosing Regimens - NAPLEX

  1. A 63-year-old man (88 kg, 180 cm) with chronic kidney disease stage 4 presents with acute gout flare (podagra) and significant pain for 24 hours. Current medications: allopurinol 100 mg PO daily, furosemide 40 mg PO daily, amlodipine 10 mg PO daily. Allergies: none. Labs: SCr 3.0 mg/dL (0.6–1.3), estimated CrCl 22 mL/min, AST/ALT WNL. The prescriber wants to use colchicine for the acute flare. Which factor requires dose adjustment in this patient?
    Answer: Renal impairment (CrCl 22 mL/min) requires colchicine dose reduction/avoidance of repeat courses This question tests factors requiring dose adjustment for colchicine in acute gout flare management. Key patient-specific factors include CKD stage 4 with CrCl 22 mL/min, increasing toxicity risk, and concomitant medications like allopurinol not directly interacting but highlighting chronic gout. The best choice is renal impairment necessitating dose reduction or avoidance of repeat courses, as guidelines (e.g., ACR) recommend lower doses (e.g., 0.6 mg once) in CrCl <30 mL/min to prevent myotoxicity and neuropathy. Option B misapplies weight-based dosing, irrelevant for colchicine; option C incorrectly suggests increasing dose with normal liver function; option D overstates amlodipine interaction, which warrants caution but not contraindication. These distractors highlight misconceptions about pharmacokinetics in organ dysfunction. A pearl is to calculate CrCl for colchicine dosing, limiting total dose in impaired patients. Framework: Assess renal/hepatic function and drug interactions (CYP3A4/P-gp) before prescribing anti-inflammatories for flares.
  2. A 52-year-old man (84 kg, 173 cm) with newly diagnosed hypertension is started on chlorthalidone. Current medications: none. Allergies: none. Labs: Na 140 mEq/L, K 4.2 mEq/L, SCr 0.9 mg/dL (0.6–1.3), A1c 5.6%. BP in clinic averages 152/94 mmHg. What is the most appropriate initial dose for chlorthalidone?
    Answer: Chlorthalidone 12.5 mg PO daily This question tests the appropriate initial dosing for chlorthalidone in hypertension. Key patient-specific factors include new diagnosis, normal electrolytes/renal function, and BP 152/94 mmHg requiring therapy. The best choice is chlorthalidone 12.5 mg PO daily, as ACC/AHA guidelines recommend starting low (12.5-25 mg) for thiazides to minimize electrolyte disturbances while controlling BP. Option B overdoses at 100 mg; option C uses excessive frequency; option D under-doses at 2.5 mg. These distractors misapply dosing ranges. A pearl is to monitor potassium and renal function post-initiation. Framework: Titrate antihypertensives based on BP response and tolerability.
  3. A 58-year-old female (74 kg, 165 cm) with nonvalvular atrial fibrillation is seen in clinic for anticoagulation selection. Current medications: diltiazem ER 240 mg PO daily, hydrochlorothiazide 25 mg PO daily, omeprazole 20 mg PO daily. Allergies: none. History: hypertension, chronic kidney disease stage 4. Labs: SCr 2.6 mg/dL (0.6–1.1), estimated CrCl 22 mL/min, AST/ALT 28/24 U/L (normal), Hgb 12.4 g/dL. She has no mechanical heart valve and no moderate-to-severe mitral stenosis. What is the appropriate dosing regimen for this medication (apixaban) for stroke prevention in this patient?
    Answer: Apixaban 5 mg PO twice daily This question tests appropriate apixaban dosing for stroke prevention in nonvalvular atrial fibrillation with renal impairment. Key patient-specific factors include severe renal impairment (CrCl 22 mL/min), age 58 years, weight 74 kg, and absence of other dose-reduction criteria. Apixaban 5 mg PO twice daily is correct because the patient meets only ONE of the three criteria for dose reduction (age ≥80 years, weight ≤60 kg, or SCr ≥1.5 mg/dL) - her SCr is 2.6 mg/dL. Apixaban requires dose reduction to 2.5 mg twice daily only when TWO or more criteria are met. Choice A (10 mg twice daily for 7 days) is the treatment dose for acute VTE, not atrial fibrillation stroke prevention. Choices B and D represent inappropriate dose reductions since only one criterion is met. The clinical pearl is that apixaban dose reduction for atrial fibrillation requires meeting at least TWO of three specific criteria, unlike other DOACs which may have different renal cutoffs, and severe renal impairment alone (even with CrCl <25 mL/min) does not automatically mandate dose reduction if other criteria are absent.
  4. A 34-year-old woman (62 kg, 168 cm) presents with a painful vesicular rash in a dermatomal distribution on the right torso for 36 hours consistent with herpes zoster. Current medications: ethinyl estradiol/levonorgestrel 1 tab PO daily. Allergies: none. Labs: SCr 0.8 mg/dL (0.6–1.3), eGFR 105 mL/min/1.73 m², AST/ALT WNL. What is the appropriate dosing regimen for valacyclovir for this indication?
    Answer: Valacyclovir 1 g PO three times daily for 7 days This question tests the appropriate dosing regimen for valacyclovir in herpes zoster (shingles) treatment. Key patient-specific factors include age 34 years, normal renal function (eGFR 105 mL/min/1.73 m²), and rash onset within 36 hours, allowing optimal antiviral efficacy. The best choice is valacyclovir 1 g PO three times daily for 7 days, as IDSA and CDC guidelines recommend this for immunocompetent adults to reduce pain duration and postherpetic neuralgia risk when started within 72 hours. Option A is the genital herpes regimen, too low for zoster; option C uses suppression dosing; option D is for cold sores, insufficient duration. These distractors confuse indications across herpesvirus infections. A clinical pearl is to initiate antivirals promptly in zoster for best outcomes, adjusting for renal impairment if CrCl <50 mL/min. For similar decisions, differentiate dosing by virus type and patient immunity status per guidelines.
  5. A 55-year-old woman (73 kg, 163 cm) with GERD has been taking omeprazole 20 mg PO daily for 18 months without reassessment and now reports symptom control. Current medications: omeprazole 20 mg PO daily, calcium citrate 500 mg PO daily. Allergies: none. Labs: Mg 1.6 mg/dL (1.7–2.2), SCr 0.8 mg/dL, AST/ALT WNL. Which chronic medication management approach is most appropriate?
    Answer: Attempt step-down (e.g., lower dose or intermittent/on-demand use) and reassess need for chronic PPI therapy This question tests appropriate management of chronic PPI therapy in GERD. Key patient-specific factors include 18 months use, symptom control, and low magnesium, raising long-term risk concerns. The best choice is to attempt step-down to lower dose or on-demand, per AGA guidelines to minimize risks like hypomagnesemia while reassessing need. Option A continues indefinitely, ignoring risks; option C increases unnecessarily; option D switches to less effective H2RA. These distractors overlook deprescribing. A pearl is to monitor for PPI adverse effects annually. Framework: Use lowest effective dose/duration for acid suppression.
  6. A 64-year-old man (85 kg, 175 cm) with chronic obstructive pulmonary disease (COPD) is started on tiotropium HandiHaler for maintenance therapy. Current medications: albuterol HFA 2 puffs q4–6h PRN, fluticasone/salmeterol 250/50 mcg 1 inhalation BID. Allergies: none. Labs: SCr 1.2 mg/dL, AST/ALT WNL. What is the appropriate dosing regimen for tiotropium HandiHaler?
    Answer: Inhale the contents of 1 capsule (18 mcg) once daily using the HandiHaler device This question tests the appropriate dosing regimen for tiotropium HandiHaler in COPD maintenance. Key patient-specific factors include COPD diagnosis, concomitant inhalers, and normal labs allowing standard use. The best choice is to inhale 1 capsule (18 mcg) once daily via HandiHaler, as GOLD guidelines recommend this LAMA dose for bronchodilation. Option B doubles dose/frequency; option C is PRN; option D suggests swallowing, incorrect. These distractors misapply administration. A pearl is to pierce capsules only in device. Framework: Optimize inhaler technique for COPD controllers.
  7. A 19-year-old man (72 kg, 180 cm) presents to a pharmacy clinic for routine immunization review before starting college and living in a dormitory. Current medications: none. Allergies: none. Vaccination history: completed childhood series; received Tdap at age 11; no meningococcal B vaccine documented. Labs: not applicable. Which vaccine is indicated now based on dormitory living risk and age?
    Answer: Meningococcal conjugate (MenACWY) booster if not received at age 16 This question tests the appropriate vaccine indication based on age and risk factors. Key patient-specific factors include age 19 years, dormitory living increasing meningococcal risk, and incomplete vaccination history. The best choice is meningococcal conjugate (MenACWY) booster if not received at 16, as CDC recommends for adolescents/young adults in high-risk settings like colleges. Option B is for age ≥50; option C for ≥65 or risk; option D similarly age-based. These distractors confuse age/risk indications. A pearl is to verify adolescent boosters for college entry. Framework: Assess lifestyle risks for vaccine recommendations.
  8. A 41-year-old woman (68 kg, 170 cm) with major depressive disorder has had inadequate response to sertraline 100 mg PO daily after 8 weeks and reports persistent symptoms. Current medications: sertraline 100 mg PO daily. Allergies: none. Labs: TSH WNL, SCr 0.8 mg/dL, AST/ALT WNL. The prescriber plans to switch to venlafaxine XR. What is the most appropriate initial dose for venlafaxine XR in an adult?
    Answer: Venlafaxine XR 37.5 mg PO daily This question tests the appropriate initial dosing for venlafaxine XR in major depressive disorder. Key patient-specific factors include inadequate response to sertraline, normal labs, and adult status. The best choice is venlafaxine XR 37.5 mg PO daily, as APA guidelines and labeling recommend starting low and titrating to minimize side effects like hypertension. Option B starts too high; option C exceeds daily max; option D uses IR form incorrectly. These distractors ignore titration needs. A pearl is to monitor BP during SNRI initiation. Framework: Escalate antidepressants gradually, assessing response every 4-6 weeks.
  9. A 83-year-old woman (50 kg, 155 cm) with chronic pain is prescribed gabapentin for postherpetic neuralgia. Current medications: acetaminophen 650 mg PO every 6 hours PRN, amlodipine 5 mg PO daily. Allergies: none. Labs: SCr 1.4 mg/dL (0.6–1.3), estimated CrCl 25 mL/min, AST/ALT WNL. What is the most appropriate initial dosing approach for gabapentin in this patient?
    Answer: Start gabapentin at a reduced dose/frequency due to CrCl 25 mL/min and titrate as tolerated This question tests the appropriate initial dosing approach for gabapentin in postherpetic neuralgia. Key patient-specific factors include age 83 years, low weight 50 kg, and CrCl 25 mL/min requiring renal adjustment. The best choice is to start at reduced dose/frequency and titrate, as guidelines recommend 100-300 mg daily in severe impairment to avoid sedation/accumulation. Option B ignores renal function; option C uses PRN incorrectly; option D dismisses renal impact. These distractors overlook adjustments. A pearl is to calculate CrCl for renally cleared drugs in elderly. Framework: Titrate neuromodulators slowly, monitoring CNS effects.
  10. A 52-year-old male (86 kg, 175 cm) is being treated for a provoked DVT and is transitioning from parenteral anticoagulation to warfarin. Current medications: enoxaparin 1 mg/kg subcutaneously every 12 hours (started 2 days ago), warfarin 5 mg PO daily (started today), acetaminophen 650 mg PO every 6 hours as needed. Allergies: none. History: DVT after surgery, no liver disease. Labs: INR 1.1 (goal 2–3), SCr 0.8 mg/dL (0.7–1.3), AST/ALT 24/26 U/L (normal). What is the appropriate dosing regimen for enoxaparin overlap with warfarin in this patient?
    Answer: Continue enoxaparin for at least 5 days AND until INR is therapeutic (≥2.0) for at least 24 hours This question tests proper bridging therapy when transitioning from parenteral anticoagulation to warfarin. The key principle is that warfarin requires several days to achieve therapeutic anticoagulation due to the half-lives of clotting factors, necessitating overlap with parenteral therapy. Choice B is correct: enoxaparin must be continued for at least 5 days AND until the INR is therapeutic (≥2.0) for at least 24 hours, ensuring adequate anticoagulation throughout the transition. Choice A is incorrect because stopping after only 2 days would leave the patient inadequately anticoagulated. Choice C is incorrect as reducing the enoxaparin dose would provide subtherapeutic anticoagulation during the overlap period. Choice D is incorrect because an INR >3.0 exceeds the therapeutic range and immediate discontinuation without confirming stability could lead to subtherapeutic anticoagulation. The clinical pearl is that both time (minimum 5 days) and therapeutic INR (at goal for 24 hours) criteria must be met before discontinuing parenteral anticoagulation, as warfarin's initial effect on INR doesn't reflect full anticoagulation due to protein C depletion preceding factor II depletion.
  11. A 45-year-old man (80 kg, 180 cm) presents with an acute asthma exacerbation requiring oral corticosteroids after increased albuterol use. Current medications: budesonide/formoterol 160/4.5 mcg 2 inhalations BID, albuterol HFA 2 puffs q4h PRN. Allergies: none. Labs: SCr 0.9 mg/dL, AST/ALT WNL. What is the appropriate dosing regimen for prednisone for an adult outpatient asthma exacerbation?
    Answer: Prednisone 40–60 mg PO daily for 5–7 days This question tests the appropriate dosing regimen for oral prednisone in acute asthma exacerbation. Key patient-specific factors include adult status, outpatient management, and normal labs allowing standard therapy. The best choice is prednisone 40-60 mg PO daily for 5-7 days, as GINA guidelines recommend this short burst for adults to resolve inflammation without taper. Option B is low-dose chronic; option C is single high dose; option D alternates incorrectly. These distractors misapply duration/intensity. A pearl is to avoid prolonged courses to minimize side effects. Framework: Base corticosteroid dosing on severity and response in respiratory flares.
  12. A 56-year-old woman (66 kg, 164 cm) with rheumatoid arthritis is starting methotrexate for disease control. Current medications: folic acid 1 mg PO daily, ibuprofen 400 mg PO TID PRN. Allergies: none. Labs: AST 22 U/L, ALT 24 U/L, SCr 0.8 mg/dL, CBC WNL. What is the most appropriate initial dose for oral methotrexate in an adult with RA?
    Answer: Methotrexate 7.5–15 mg PO once weekly This question tests the appropriate initial dosing for oral methotrexate in rheumatoid arthritis. Key patient-specific factors include adult status, normal labs, and concomitant folic acid to mitigate toxicity. The best choice is methotrexate 7.5-15 mg PO once weekly, as ACR guidelines recommend this starting range with weekly dosing for efficacy and safety. Option B uses daily, risking toxicity; option C is PRN; option D alters frequency incorrectly. These distractors misapply schedule. A pearl is to supplement folic acid weekly. Framework: Monitor labs quarterly for DMARDs in autoimmune diseases.
  13. A 58-year-old man (102 kg, 175 cm) with type 2 diabetes and established ASCVD (prior MI) is on maximally tolerated statin therapy. Current medications: atorvastatin 80 mg PO nightly, aspirin 81 mg PO daily, metformin 1000 mg PO BID, metoprolol succinate 100 mg PO daily. Allergies: none. Labs: LDL-C 98 mg/dL, A1c 7.4%, SCr 1.0 mg/dL (0.6–1.3), AST/ALT WNL. Which medication is indicated to further reduce LDL-C and ASCVD risk in this patient?
    Answer: Ezetimibe 10 mg PO daily This question tests the appropriate add-on therapy for LDL-C reduction in a patient with ASCVD and diabetes on maximal statin. Key patient-specific factors include LDL-C 98 mg/dL above goal (<70 mg/dL), obesity, and normal renal/liver function. The best choice is ezetimibe 10 mg PO daily, as ACC/AHA guidelines recommend it as first-line non-statin for high-risk patients to further lower LDL-C and CV risk via cholesterol absorption inhibition. Option B risks myopathy with statin; option C may worsen diabetes; option D is for triglycerides, not LDL-C. These distractors confuse lipid targets and drug mechanisms. A pearl is to target LDL-C <70 mg/dL in ASCVD, adding ezetimibe if needed. Framework: Use stepwise intensification based on risk and response monitoring.
  14. A 48-year-old man (110 kg, 178 cm) with type 2 diabetes and albuminuria is being considered for an ACE inhibitor for renal protection. Current medications: amlodipine 10 mg PO daily, metformin 1000 mg PO BID. Allergies: none. Labs: urine albumin-to-creatinine ratio 220 mg/g, SCr 1.0 mg/dL, K 4.4 mEq/L, BP 138/84 mmHg. Which medication is indicated to slow progression of diabetic kidney disease in this patient?
    Answer: Lisinopril This question tests the appropriate medication for renal protection in diabetic kidney disease. Key patient-specific factors include albuminuria 220 mg/g, type 2 diabetes, and BP 138/84 mmHg near goal. The best choice is lisinopril, as ADA guidelines recommend ACE inhibitors to slow progression via antiproteinuric effects. Option B lacks renoprotection; option C may worsen; option D is central-acting. These distractors ignore evidence for RAAS inhibition. A pearl is to target ACR <30 mg/g with therapy. Framework: Prioritize ACEI/ARB in proteinuric DKD regardless of BP.
  15. A 60-year-old man (75 kg, 172 cm) with chronic hepatitis C-related cirrhosis (Child-Pugh C) is being evaluated for insomnia and requests a new medication. Current medications: lactulose 20 g PO TID, rifaximin 550 mg PO BID, propranolol 20 mg PO BID. Allergies: none. Labs: AST 88 U/L (10–40), ALT 52 U/L (7–56), total bilirubin 4.1 mg/dL (0.2–1.2), albumin 2.6 g/dL (3.5–5.0), INR 2.0. Which factor requires dose adjustment in this patient when selecting and dosing sedative-hypnotics?
    Answer: Severe hepatic impairment (Child-Pugh C) This question tests factors requiring dose adjustment for sedative-hypnotics in insomnia. Key patient-specific factors include Child-Pugh C cirrhosis with elevated bilirubin/INR and low albumin, impairing metabolism. The best choice is severe hepatic impairment necessitating lower doses or avoidance, as guidelines recommend caution with hypnotics like zolpidem (start 5 mg) to prevent excessive sedation. Option B misapplies weight; option C ignores relevance; option D confuses lactulose effects. These distractors overlook pharmacokinetics. A pearl is to use Child-Pugh score for dosing in liver disease. Framework: Adjust for organ function in CNS drugs to avoid toxicity.
  16. A 70-year-old man (78 kg, 172 cm) with benign prostatic hyperplasia (BPH) reports nocturia and weak stream despite tamsulosin. Current medications: tamsulosin 0.4 mg PO daily, hydrochlorothiazide 25 mg PO daily. Allergies: none. Labs: SCr 1.0 mg/dL, PSA 1.8 ng/mL, BP 124/76 mmHg. The prescriber plans to increase tamsulosin. What is the appropriate dosing regimen adjustment for tamsulosin?
    Answer: Increase to tamsulosin 0.8 mg PO once daily if inadequate response after 2–4 weeks This question assesses the appropriate dosing regimen adjustment for tamsulosin in managing benign prostatic hyperplasia (BPH) symptoms. Key patient-specific factors include the patient's age, persistent nocturia and weak stream despite initial therapy, normal renal function (SCr 1.0 mg/dL), and stable blood pressure, indicating tolerance to alpha-blocker escalation without significant orthostatic risk. Increasing to tamsulosin 0.8 mg PO once daily if inadequate response after 2–4 weeks is the best choice, aligning with FDA-approved labeling and AUA guidelines for BPH, which recommend titrating from 0.4 mg to a maximum of 0.8 mg daily with a monitoring period to assess efficacy and side effects. Immediately increasing to 1.6 mg (choice B) exceeds the maximum recommended dose and risks adverse effects like hypotension; changing to 0.4 mg twice daily (choice C) is inappropriate as tamsulosin is formulated for once-daily extended-release administration. Adding a second alpha-1 blocker like doxazosin (choice D) is suboptimal without first maximizing tamsulosin monotherapy and could increase side effect burden unnecessarily. A transferable clinical pearl is that alpha-blockers for BPH should be titrated gradually to balance symptom relief with minimizing dizziness or hypotension, especially in older adults. In practice, employ a stepwise framework: evaluate response after 2-4 weeks at starting dose, titrate to max if needed, and consider combination therapy only if monotherapy fails.
  17. A 67-year-old man (82 kg, 178 cm) presents to urgent care with dysuria, urinary frequency, and suprapubic discomfort for 2 days; he is afebrile and denies flank pain. Current medications: metformin 1000 mg PO BID, lisinopril 20 mg PO daily, atorvastatin 40 mg PO nightly. Allergies: TMP-SMX (hives). Labs: SCr 1.8 mg/dL (0.6–1.3), eGFR 38 mL/min/1.73 m², AST/ALT WNL. Urinalysis: positive leukocyte esterase and nitrites. What is the appropriate dosing regimen for nitrofurantoin monohydrate/macrocrystals for this patient?
    Answer: Nitrofurantoin 100 mg PO twice daily for 5 days This question tests the appropriate dosing regimen for nitrofurantoin in the treatment of uncomplicated urinary tract infection (UTI) in a male patient. Key patient-specific factors include age 67 years, male gender, eGFR 38 mL/min/1.73 m² indicating moderate renal impairment, and allergy to TMP-SMX limiting alternative options. The best choice is nitrofurantoin 100 mg PO twice daily for 5 days, as IDSA guidelines recommend this regimen for uncomplicated cystitis in adults when susceptibility is likely and renal function permits, with evidence supporting efficacy in males for 5-7 days despite traditional views of male UTIs as complicated. Option A uses a lower dose and shorter duration more suited for older formulations or pediatric use, making it suboptimal for efficacy; option C extends to 10-14 days, which is reserved for complicated UTIs or pyelonephritis; option D employs a prophylactic dose inadequate for acute treatment. These distractors highlight misconceptions about duration in uncomplicated vs. complicated infections and formulation-specific dosing. A clinical pearl is to always assess renal function before nitrofurantoin use, avoiding it if CrCl <30 mL/min due to risk of subtherapeutic levels and toxicity. For similar decisions, calculate eGFR and consider gender-specific UTI classification per AUA guidelines to guide duration.
  18. A 70-year-old female (58 kg, 162 cm) with rheumatoid arthritis is prescribed methotrexate by her rheumatologist and asks the pharmacist how to take it. Current medications: prednisone 5 mg PO daily, folic acid 1 mg PO daily, omeprazole 20 mg PO daily, calcium/vitamin D supplement daily. Allergies: none. History: rheumatoid arthritis, osteoporosis. Labs: SCr 0.9 mg/dL (0.6–1.1), AST/ALT 32/35 U/L (normal), CBC: WBC 6.2 x103x10^3/µL, platelets 240 x103x10^3/µL. What is the appropriate dosing regimen for oral methotrexate initiation for rheumatoid arthritis in this patient?
    Answer: Methotrexate 7.5 mg PO once weekly This question tests appropriate methotrexate dosing for rheumatoid arthritis. Methotrexate for RA is dosed WEEKLY, not daily, starting at 7.5-10 mg once weekly with gradual titration based on response and tolerability. Choice B (7.5 mg PO once weekly) is correct as it represents an appropriate starting dose for RA with weekly administration. Choice A (2.5 mg daily) would result in dangerous daily dosing and potential fatal toxicity. Choice C (25 mg twice daily) represents an extremely toxic daily regimen that would cause severe myelosuppression and mucositis. Choice D (15 mg every other day) uses an inappropriate dosing interval that could lead to confusion and potential daily dosing errors. The concurrent folic acid supplementation helps reduce methotrexate toxicity without compromising efficacy. The clinical pearl is that methotrexate for rheumatoid arthritis must ALWAYS be dosed weekly (never daily), medication errors with daily dosing have resulted in fatal outcomes, and clear patient education with written instructions specifying "ONCE WEEKLY" dosing is essential for safety.
  19. A 76-year-old woman (58 kg, 158 cm) with chronic atrial fibrillation is taking warfarin for stroke prevention. Current medications: warfarin 5 mg PO daily, amiodarone 200 mg PO daily, levothyroxine 75 mcg PO daily. Allergies: none. Labs: INR 4.8 (goal 2–3), Hgb 11.8 g/dL, AST/ALT WNL, SCr 0.9 mg/dL. She reports no bleeding. What is the most appropriate warfarin management today?
    Answer: Hold 1–2 doses of warfarin and resume at a lower weekly dose; recheck INR within about 1 week This question tests appropriate management of supratherapeutic INR on warfarin without bleeding. Key patient-specific factors include INR 4.8 (goal 2-3), no bleeding, stable Hgb, and amiodarone interaction potentiating warfarin. The best choice is to hold 1-2 doses and resume at lower weekly dose with recheck in 1 week, per ACCP guidelines for minor elevations to safely lower INR without over-correction. Option A ignores elevation, risking bleed; option C uses vitamin K unnecessarily for asymptomatic cases; option D stops permanently, inappropriate for AF. These distractors over- or under-react to INR. A pearl is to adjust warfarin by 10-20% weekly for deviations. Framework: Use INR trends and factors like drugs/diet for dose decisions.
  20. A 57-year-old woman (74 kg, 169 cm) with hypothyroidism has been stable on levothyroxine for years but recently started taking ferrous sulfate for iron deficiency anemia. Current medications: levothyroxine 100 mcg PO daily, ferrous sulfate 325 mg PO daily, pantoprazole 40 mg PO daily. Allergies: none. Labs: TSH 7.8 mIU/L (0.4–4.5), free T4 low-normal, Hgb 10.2 g/dL. Which dosing administration change is most appropriate to optimize levothyroxine therapy?
    Answer: Separate levothyroxine from ferrous sulfate by at least 4 hours This question tests the clinical pharmacy concept of managing drug interactions that affect levothyroxine absorption and efficacy in hypothyroidism treatment. Key patient-specific factors include the recent initiation of ferrous sulfate, which can bind to levothyroxine in the gastrointestinal tract, reducing its absorption, as evidenced by the elevated TSH and low-normal free T4 levels despite stable prior therapy. Separating levothyroxine from ferrous sulfate by at least 4 hours is the best choice, as recommended by guidelines from the American Thyroid Association, to minimize interaction and restore euthyroid status without altering doses. Taking them together with breakfast (choice A) would exacerbate the interaction, further decreasing levothyroxine bioavailability and worsening hypothyroidism. Replacing levothyroxine with liothyronine (choice C) is incorrect as it does not address the interaction and liothyronine is not preferred for routine hypothyroidism management due to its short half-life; skipping doses on weekends (choice D) would lead to inconsistent thyroid hormone levels and potential hypothyroidism symptoms. A key clinical pearl is to always assess for absorption-interfering agents like iron, calcium, or proton pump inhibitors in patients with unexplained TSH elevations on levothyroxine. For similar scenarios, use a systematic framework: identify the interacting agent, quantify the interaction severity, and implement separation strategies or alternative therapies based on evidence-based guidelines.

Start this quiz